Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experience with non-Hodgkin's lymphoma]

P Biron1, J P Droz

  • 1Département de cancérologie médicale, centre Léon-Bérard, Lyon, France.

Bulletin Du Cancer
|January 1, 1995
PubMed
Summary

High-dose chemotherapy with autologous bone-marrow transplantation shows activity in non-Hodgkin lymphoma. While not favored for first remission consolidation, pilot studies suggest benefit for reponder patients, with PARMA protocol results pending.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature.

Cancer treatment reviews·2021
Same author

Occupational exposures in rare cancers: A critical review of the literature.

Critical reviews in oncology/hematology·2014
Same author

Management of brain metastases from germ cell tumors: a single center experience.

Oncology·2013
Same author

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Treatment of uncommon malignant tumours of the bladder.

Current opinion in urology·2011
Same author

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Area of Science:

  • Hematology
  • Oncology

Background:

  • High-dose chemotherapy with autologous bone-marrow transplantation (HDC-ABMT) is a recognized treatment modality.
  • Its role in non-Hodgkin lymphoma (NHL) management is under investigation, particularly in specific patient subgroups.

Purpose of the Study:

  • To evaluate the efficacy of HDC-ABMT in NHL patients.
  • To clarify the role of HDC-ABMT in consolidating first complete remission versus treating reponder patients.

Main Methods:

  • Review of randomized trials assessing HDC-ABMT for first complete remission consolidation.
  • Analysis of preliminary results from pilot studies in reponder patients.

Main Results:

  • Randomized trials do not currently support HDC-ABMT for consolidating first complete remission in NHL.
  • Preliminary data from pilot studies indicate potential benefit in patients who respond to initial therapy.

Conclusions:

  • The utility of HDC-ABMT in NHL requires further investigation.
  • The PARMA protocol results are anticipated to provide definitive answers regarding HDC-ABMT's role.

Related Experiment Videos